Changchun High-Tech Industry (SHE:000661) subsidiary GeneScience obtained China's regulatory approval to conduct clinical trials for GenSci155 injection.
The drug is indicated for preventing bronchopulmonary dysplasia in premature infants and treating acute ischemic stroke, according to a Thursday filing with the Shenzhen bourse.
Shares of the drug manufacturer closed 2% lower Thursday.